Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.
about
Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Melanoma Immunotherapy: Next-Generation Biomarkers.A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
P2860
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Whole-blood RNA transcript-bas ...... point inhibitor, tremelimumab.
@en
type
label
Whole-blood RNA transcript-bas ...... point inhibitor, tremelimumab.
@en
prefLabel
Whole-blood RNA transcript-bas ...... point inhibitor, tremelimumab.
@en
P2093
P2860
P1476
Whole-blood RNA transcript-bas ...... kpoint inhibitor, tremelimumab
@en
P2093
Alan M Christenfeld
Chrisann Kyi
David Fisher
John M Kirkwood
Karl Wassmann
Nina Bhardwaj
William K Oh
P2860
P2888
P356
10.1186/S40425-017-0272-Z
P577
2017-08-15T00:00:00Z
P6179
1091112201